FDA Approves Genentech’s Gazyva® for Lupus Nephritis, Marking Breakthrough in Autoimmune Kidney Care
NEW YORK, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
NEW YORK, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by...
BOERNE, Texas, Oct. 8, 2025 – Prytime Medical Devices, Inc., a leader in endovascular hemorrhage control and resuscitation, announced...
TORINO, Italy – October 2, 2025 – AorticLab has achieved a major milestone with the U.S. Food and Drug...
Parsippany, NJ – September 30, 2025 – Zoetis Inc. announced that Dectomax®-CA1 Injectable has received conditional approval from the...
North Chicago, IL – September 30, 2025 – AbbVie (NYSE: ABBV) announced the submission of a Biologics License Application...
